Research & Development (R&D) plays a pivotal role in Actavis’ growth. The division’s work fuels the future portfolio of products for the market.

R&D also supports business development efforts by evaluating the opportunities that in-licensing brings to the Company and participating in the project selection process.

Actavis’ R&D division assists the business in ensuring that products brought to market are manufactured within the cost margins necessary to take the business forward by supporting product transfers and the introduction of new active pharmaceutical ingredients.

The Company is constantly gaining access to new markets through acquisitions, and it works to ensure that all products are cross-registered.

Actavis’ ongoing strategy for product selection is to develop profitable products for fast-growing and sustainable market sectors.

In-licensing
In a sector where the Intellectual Property (IP) landscape is becoming more complex and regulatory approval times are lengthening, Actavis continues to be vigilant in bringing its products to market faster and more efficiently.

The main objective of Actavis’ In-licensing department is to source as many products as needed, in addition to in-house development projects, so as to meet the Company’s organic growth targets. The department aims to ensure that these products are sourced from the most reliable and cost-efficient suppliers at favourable and flexible supply terms. Actavis employs regular monitoring and contract re-negotiations in order to achieve this.